Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$4.23 USD
+0.08 (1.93%)
Updated May 13, 2024 04:00 PM ET
After-Market: $4.28 +0.05 (1.18%) 5:10 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STRO 4.23 +0.08(1.93%)
Will STRO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Other News for STRO
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma reports Q1 EPS (95c), consensus (92c)
BofA starts Sutro at buy, cites ovarian cancer drug candidate
Lululemon initiated, Block upgraded: Wall Street's top analyst calls
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts